论文部分内容阅读
目的通过大肠癌患者在化疗前和化疗结束时的血常规检验指标的变化以及其与HLA-DRB1、DQB1多态性的关联,以期找到大肠癌化疗副损伤的相关的基因。方法选取100例大肠癌患者,采用多聚酶链反应-序列特异性引物(PCR-SSP)法检测其HLA-DRB1、DQB1的多态性。同时检测大肠癌患者化疗前和化疗结束时的血常规检验指标,包括:WBC、RBC、HGB、PLT、NEUT#、LYM#等。结果 HLA-DRB1*07有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DRB1*08有可能是化疗对RBC、HGB损伤的抵抗基因,同时也可能是化疗对LYM#损伤的敏感基因;HLA-DRB1*09有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DRB1*12有可能是化疗对RBC、HGB损伤的抵抗基因;HLA-DQB1*02有可能是化疗对RBC、HGB损伤的抵抗基因,同时也可能是化疗对WBC、NEUT#损伤的敏感基因;HLA-DQB1*05有可能是化疗对HGB损伤的抵抗基因,同时也可能是化疗对NEUT#损伤的敏感基因;HLA-DQB1*06有可能是化疗对HGB损伤的抵抗基因;HLA-DQB1*07有可能是化疗对RBC、HGB损伤的抵抗基因。结论 HLA可能是肿瘤化疗副损伤的标志性基因。
OBJECTIVE: To detect the changes of blood tests and the association with HLA-DRB1 and DQB1 polymorphisms in patients with colorectal cancer before chemotherapy and at the end of chemotherapy so as to find out the genes related to chemotherapy-induced side effects of colorectal cancer. Methods 100 cases of colorectal cancer were selected and the polymorphisms of HLA-DRB1 and DQB1 were detected by polymerase chain reaction-sequence-specific primers (PCR-SSP). At the same time, the blood test indexes of patients with colorectal cancer before chemotherapy and at the end of chemotherapy were detected, including WBC, RBC, HGB, PLT, NEUT # and LYM #. Results HLA-DRB1 * 07 may be the resistance gene of chemotherapy for RBC and HGB injury. HLA-DRB1 * 08 may be the resistance gene of chemotherapy for RBC and HGB injury, and may be the sensitive gene of chemotherapy for LYM # injury. HLA-DRB1 * 09 may be chemotherapy resistance to RBC, HGB injury; HLA-DRB1 * 12 may be chemotherapy resistance to RBC, HGB injury; HLA-DQB1 * 02 may be chemotherapy on RBC, HGB damage , And it may also be a sensitive gene for the chemotherapy of WBC and NEUT # injury. HLA-DQB1 * 05 may be the resistance gene for HGB injury induced by chemotherapy and may also be a sensitive gene for the damage of NEUT # induced by chemotherapy. HLA- DQB1 * 06 may be the resistance gene of HGB injury induced by chemotherapy; HLA-DQB1 * 07 may be the resistance gene of chemotherapy to RBC and HGB injury. Conclusion HLA may be a landmark gene for chemotherapy-induced side effects.